Genmab — Juli 2016
-
-
"..patients with early stage disease, who had received only 1 prior line of therapy, and/or had not received prior bortezomib, had a PFS advantage. Dr. Palumbo says these results support the use of daratumumab earlier in the disease course."
-
Kongetallet i massivt comeback.
http://borsen.dk/nyheder/oekonomi/artikel/1/327646/kongetallet_goer_massivt_comeback_287000_nye_job_i_usa.html -
Bristol Myers' small deal underscores how hot immuno-oncology is - MedCity News
BMS' purchase of Cormorant shows that no deal is too small when it comes to immuno-oncology.
MedCity News (medcitynews.com)
-
Er overrasket over at HSBC kunne ligge en dæmper på aktien efter den latterlige kursmål. Jeg forstår ikke man tage sådan et kursmål seriøst, og undrer mig over at den ikke stiger mere i et ellers positivt marked.
-
@Sukkeralfie / Fra BMSs site: "The rights to HuMax-IL8 were acquired by Cormorant from Genmab A/S in 2012 under an exclusive license agreement". Skal det forstås sådan, at (patent-)ejerskabet stadig er GENs, men at al brug og udvikling af proteinet er solgt til BMS?
-
Og er det først og fremmest afhængigt af teknologi-typen (et protein/en fremføringsmekanisme) hvor høj royalty-satsen er? (mener jeg på et tidspunkt hørte, at NOVO skulle betale 1% til Emisphere for brugen af deres 'orale-afleverings-platform', Eligen, ved fremtidigt salg af evt. Oralts Semaglutid)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind